A safe GLP-1 program should include medical evaluation, dosing guidance, follow-up support, refill coordination, and monitoring for side effects
189 Subsequently, tirzepatide has been extensively investigated in the SURPASS program, a comprehensive development initiative targeting T2DM that is inadequately controlled by various glucose-lowering regimens, including lifestyle alone (SURPASS-1), 190 metformin monotherapy (SURPASS-2), 191 metformin with or without sodium-glucose co-transporter 2 inhibitors (SGLT2i) (SURPASS-3), 192 combination therapy including metformin, SGLT2i, and sulfonylureas (SURPASS-4), 193 insulin glargine with or without metformin (SURPASS-5), 88 and insulin lispro with basal insulin (SURPASS-6)
Are blends customized
Patients should aim for adequate daily protein intake, generally 0.8-1.2 grams per kilogram of body weight according to the Academy of Nutrition and Dietetics